miR‑145 and miR‑23b co‑transfection decreases proliferation, migration, invasion and protein levels of c‑MYC, ZEB1 and ABCB1 in epithelial ovarian cancer cell lines

Fredes‑Garrido,Allison; Cruz,Álvaro Armijo; Calaf,Gloria M.; Garrido,Maritza P.; Romero,Carmen

doi:10.3892/mmr.2025.13611

miR‑145 and miR‑23b co‑transfection decreases proliferation, migration, invasion and protein levels of c‑MYC, ZEB1 and ABCB1 in epithelial ovarian cancer cell lines

Authors:
- Allison Fredes‑Garrido
- Álvaro Armijo Cruz
- Gloria M. Calaf
- Maritza P. Garrido
- Carmen Romero
View Affiliations

Affiliations: Laboratory of Endocrinology and Reproductive Biology, Clinical Hospital University of Chile, Santiago 8380456, Chile, Institute of Advanced Research, University of Tarapacá, Arica 1000000, Chile
Published online on: July 8, 2025 https://doi.org/10.3892/mmr.2025.13611
Article Number: 246
Copyright: © Fredes‑Garrido et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) are non‑coding RNAs that prevent the translation of mRNAs. miRs participate in cellular processes such as cell proliferation, migration and invasion, acting as oncogenes or tumor suppressors. In epithelial ovarian cancer (EOC), a decrease in tumor suppressor miRs, such as miR‑145 and miR‑23b, regulates the mRNAs of oncogenic proteins. The present study aimed to determine whether the co‑transfection of two oncosuppressor miRs (miR‑145‑5p and miR‑23b‑3p) decreased the proliferation, migration, invasion, and protein levels of c‑MYC, zinc finger E‑box binding homeobox 1 (ZEB1) and ATP binding cassette subfamily B1 (ABCB1) in EOC cell lines (A2780, SKOV‑3 and OV‑90). Reverse transcription‑quantitative PCR was employed to determine miR expression after co‑transfection. Cell proliferation was evaluated by Ki‑67 immunofluorescence staining and Ki‑67 positive cell counting. Transwell inserts, both with and without Matrigel, were used to assess invasion and migration, respectively. c‑MYC, ZEB1 and ABCB1 protein expression was determined by western blot analysis. The co‑transfection of miR‑145 and miR‑23b resulted in decreased proliferation, migration and invasion, along with reduced protein expression levels of c‑MYC, ZEB1 and ABCB1 in EOC cells. The combination of miR‑23b and miR‑145 transfection in EOC cells exhibited good antitumor effects, thus supporting the design of future complementary therapies for EOC.

View Figures

View References

1	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
2	World Ovarian Cancer Coalition, . The World Ovarian Cancer Coalition Atlas, Global Trends in Incidence, Mortality and Survival. 2023.
3	World Ovarian Cancer Coalition, . The World Ovarian Cancer Coalition Atlas, Global Trends in Incidence, Mortality and Survival. 2020.
4	Jessmon P, Boulanger T, Zhou W and Patwardhan P: Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 17:427–437. 2017. View Article : Google Scholar : PubMed/NCBI
5	Rojas V, Hirshfield KM, Ganesan S and Rodriguez-Rodriguez L: Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. Int J Mol Sci. 17:21132016. View Article : Google Scholar
6	Ledermann JA: First-line treatment of ovarian cancer: Questions and controversies to address. Ther Adv Med Oncol. 10:17588359187682322018. View Article : Google Scholar
7	Beesley VL, Ross TL, King MT, Campbell R, Nagle CM, Obermair A, Grant P, DeFazio A, Webb PM and Friedlander ML; OPAL Study Group, : Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecol Oncol. 164:437–445. 2022. View Article : Google Scholar
8	Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB and Romero C: Current treatments and new possible complementary therapies for epithelial ovarian cancer. Biomedicines. 10:772022. View Article : Google Scholar
9	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar
10	Garrido MP, Torres I, Avila A, Chnaiderman J, Valenzuela-Valderrama M, Aramburo J, Oróstica L, Durán-Jara E, Lobos-Gonzalez L and Romero C: NGF/TRKA Decrease miR-145-5p levels in epithelial ovarian cancer cells. Int J Mol Sci. 21:76572020. View Article : Google Scholar
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar
12	Vera C, Retamales-Ortega R, Garrido M, Vega M and Romero C: Signaling pathways related to nerve growth factor and miRNAs in epithelial ovarian cancer. Ovarian Cancer: From Pathogenesis to Treatment. pp392018. View Article : Google Scholar
13	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar
14	Julio-Pieper M, Lozada P, Tapia V, Vega M, Miranda C, Vantman D, Ojeda SR and Romero C: Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA Receptor/Mitogen-Activated protein Kinase-extracellularly regulated kinase 2-Dependent pathway. J Clin Endocrinol Metab. 94:3065–3071. 2009. View Article : Google Scholar : PubMed/NCBI
15	Garrido MP, Hurtado I, Valenzuela-Valderrama M, Salvatierra R, Hernández A, Vega M, Selman A, Quest AFG and Romero C: NGF-Enhanced vasculogenic properties of epithelial ovarian cancer cells is reduced by inhibition of the COX-2/PGE2 signaling axis. Cancers. 11:19702019. View Article : Google Scholar : PubMed/NCBI
16	Tapia V, Gabler F, Muñoz M, Yazigi R, Paredes A, Selman A, Vega M and Romero C: Tyrosine kinase A receptor (trkA): A potential marker in epithelial ovarian cancer. Gynecol Oncol. 121:13–23. 2011. View Article : Google Scholar
17	Urzua U, Tapia V, Geraldo MP, Selman A, Vega M and Romero C: Nerve growth factor stimulates cellular proliferation of human epithelial ovarian cancer. Horm Metab Res. 44:656–661. 2012. View Article : Google Scholar : PubMed/NCBI
18	Campos X, Muñoz Y, Selman A, Yazigi R, Moyano L, Weinstein-Oppenheimer C, Lara HE and Romero C: Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer. Gynecol Oncol. 104:168–175. 2007. View Article : Google Scholar
19	Smolarz B, Durczyński A, Romanowicz H, Szyłło K and Hogendorf P: miRNAs in Cancer (Review of Literature). Int J Mol Sci. 23:28052022. View Article : Google Scholar
20	Adams BD, Kasinski AL and Slack FJ: Aberrant regulation and function of microRNAs in cancer. Current Biology. 24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
21	Svoronos AA, Engelman DM and Slack FJ: OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
22	Tian S, Zhang M, Chen X, Liu Y and Lou G: MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Oncotarget. 7:87091–87099. 2016. View Article : Google Scholar
23	An X, Sarmiento C, Tan T and Zhu H: Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 7:38–51. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhang W, Wang Q, Yu M, Wu N and Wang H: MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat. 13:161–168. 2014. View Article : Google Scholar
25	Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ, Tafe LJ, Garg K, Oliva E, Matias-Guiu X, Soslow RA and Palacios J: ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol. 26:1514–1524. 2013. View Article : Google Scholar
26	Retamales-Ortega R, Oróstica L, Vera C, Cuevas P, Hernández A, Hurtado I, Vega M and Romero C: Role of nerve growth factor (NGF) and miRNAs in epithelial ovarian cancer. Int J Mol Sci. 18:5072017. View Article : Google Scholar
27	Romero-López MJ, Jiménez-Wences H, Cruz-De la Rosa MI, Román-Fernández IV and Fernández-Tilapa G: miR-23b-3p, miR-124-3p and miR-218-5p synergistic or additive effects on cellular processes that modulate cervical cancer progression? A molecular balance that needs attention. Int J Mol Sci. 23:135512022. View Article : Google Scholar
28	Grossi I, Arici B, Portolani N, Petro GD and Salvi A: Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma. Oncotarget. 8:6955–6969. 2016. View Article : Google Scholar
29	Pimenta RC, Viana NI, Amaral GQ, Park R, Morais DR, Pontes J Jr, Guimaraes VR, Camargo JA, Leite KR, Nahas WC, et al: MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line. Tumour Biol. 40:10104283188030112018. View Article : Google Scholar
30	Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, Zhu W, Shu Y and Liu P: MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. 588:1168–1177. 2014. View Article : Google Scholar
31	Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, et al: miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 6:e3802016. View Article : Google Scholar : PubMed/NCBI
32	Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, Fang Y, Lin X, Xu Y, Xu W, et al: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 135:1286–1296. 2014. View Article : Google Scholar : PubMed/NCBI
33	Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, Ferguson MJ and Smith G: ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 115:431–441. 2016. View Article : Google Scholar : PubMed/NCBI
34	Engle K and Kumar G: Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. Eur J Med Chem. 239:1145422022. View Article : Google Scholar : PubMed/NCBI
35	Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W and Tang J: MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci. 111:3122–3131. 2020. View Article : Google Scholar
36	Sheng Q, Zhang Y, Wang Z, Ding J, Song Y and Zhao W: Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clin Exp Immunol. 200:45–52. 2020. View Article : Google Scholar
37	Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, Tanaka Y, Dahiya R and Yamamura S: MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS One. 8:e676862013. View Article : Google Scholar : PubMed/NCBI
38	Yao D, Dai C and Peng S: Mechanism of the Mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011. View Article : Google Scholar : PubMed/NCBI
39	Fan H, Atiya HI, Wang Y, Pisanic TR, Wang TH, Shih IM, Foy KK, Frisbie L, Buckanovich RJ, Chomiak AA, et al: Epigenomic reprogramming toward Mesenchymal-epithelial transition in ovarian-Cancer-associated mesenchymal stem cells drives metastasis. Cell Rep. 33:1084732020. View Article : Google Scholar : PubMed/NCBI
40	Cui Y, Qin L, Tian D, Wang T, Fan L, Zhang P and Wang Z: ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2. Chemotherapy. 63:262–271. 2018. View Article : Google Scholar : PubMed/NCBI
41	Garrido MP, Salvatierra R, Valenzuela-Valderrama M, Vallejos C, Bruneau N, Hernández A, Vega M, Selman A, Quest AFG and Romero C: Metformin reduces NGF-induced tumour promoter effects in epithelial ovarian cancer cells. Pharmaceuticals (Basel). 13:3152020. View Article : Google Scholar : PubMed/NCBI
42	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
43	Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414–418. 1987.PubMed/NCBI
44	Tudrej P, Olbryt M, Zembala-Nożyńska E, Kujawa KA, Cortez AJ, Fiszer-Kierzkowska A, Pigłowski W, Nikiel B, Głowala-Kosińska M, Bartkowska-Chrobok A, et al: Establishment and characterization of the novel High-grade serous ovarian cancer cell line OVPA8. Int J Mol Sci. 19:20802018. View Article : Google Scholar
45	Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, et al: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 1:1400352014. View Article : Google Scholar
46	Llorens MC, Lorenzatti G, Cavallo NL, Vaglienti MV, Perrone AP, Carenbauer AL, Darling DS and Cabanillas AM: Phosphorylation regulates functions of ZEB1 transcription factor. J Cell Physiol. 231:2205–2217. 2016. View Article : Google Scholar
47	Perez-Oquendo M, Manshouri R, Tian Y, Fradette JJ, Rodriguez BL, Kundu ST and Gibbons DL: ZEB1 is regulated by K811 acetylation to promote stability, NuRD complex interactions, EMT, and NSCLC metastasis. Mol Cancer Res. 21:779–794. 2023. View Article : Google Scholar : PubMed/NCBI
48	Zhou F, Du C, Xu D, Lu J, Zhou L, Wu C, Wu B and Huang J: Knockdown of ubiquitin-specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc-finger E-box binding homeobox 1. Mol Med Rep. 22:1382–1390. 2020. View Article : Google Scholar : PubMed/NCBI
49	Zhang H, Tang H, Tu W and Peng F: Regulatory role of non-coding RNAs in 5-Fluorouracil resistance in gastrointestinal cancers. Cancer Drug Resist. 8:42025. View Article : Google Scholar
50	Yi J, Li B, Yin X, Liu L, Song C, Zhao Y, Cai M, Tang H, Chen D and Lyu N: CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression. Oncol Res. 32:1129–1139. 2024. View Article : Google Scholar : PubMed/NCBI
51	Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, Song C, Liu L, Xie X, Li Y, et al: A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 581:2165082024. View Article : Google Scholar
52	Pei X, Chen SW, Long X, Zhu SQ, Qiu BQ, Lin K, Lu F, Xu JJ, Zhang PF and Wu YB: circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by regulating the miR-145-5p/CXCL3 axis. Aging (Albany NY). 12:13038–13058. 2020. View Article : Google Scholar : PubMed/NCBI
53	Zhu Z, Wu Q, Zhang M, Tong J, Zhong B and Yuan K: Hsa_circ_0016760 exacerbates the malignant development of Non-small cell lung cancer by sponging miR-145-5p/FGF5. Oncol Rep. 45:501–512. 2021. View Article : Google Scholar : PubMed/NCBI
54	Singh S, Saxena S, Sharma H, Paudel KR, Chakraborty A, MacLoughlin R, Oliver BG, Gupta G, Negi P, Singh SK and Dua K: Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer. Pathol Res Pract. 256:1552222024. View Article : Google Scholar
55	Yan J, Jiang J, Meng XN, Xiu YL and Zong ZH: MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Cancer Res. 35:312016. View Article : Google Scholar : PubMed/NCBI
56	Zhou J, Zhang X, Li W and Chen Y: MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting SMAD4. J Ovarian Res. 13:542020. View Article : Google Scholar : PubMed/NCBI
57	Kubickova A, De Sanctis JB and Hajduch M: Isoform-directed control of c-Myc Functions: Understanding the balance from proliferation to growth arrest. Int J Mol Sci. 24:175242023. View Article : Google Scholar
58	Perez-Oquendo M and Gibbons DL: Regulation of ZEB1 function and molecular associations in tumor progression and metastasis. Cancers (Basel). 14:18642022. View Article : Google Scholar : PubMed/NCBI
59	Shao Y, Qu Y, Dang S, Yao B and Ji M: MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int. 13:512013. View Article : Google Scholar
60	Xu WX, Liu Z, Deng F, Wang DD, Li XW, Tian T, Zhang J and Tang JH: MiR-145: A potential biomarker of cancer migration and invasion. Am J Transl Res. 11:6739–6753. 2019.PubMed/NCBI
61	Seyfried TN and Huysentruyt LC: On the origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013. View Article : Google Scholar : PubMed/NCBI
62	Bravo-Cordero JJ, Hodgson L and Condeelis J: Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 24:277–283. 2012. View Article : Google Scholar
63	Cai W and Zhang Q: The transcription factor ZEB1 mediates the progression of epithelial ovarian cancer by promoting the transcription of CircANKRD17. J Biochem Mol Toxicol. 36:e230862022. View Article : Google Scholar
64	Hashiguchi M, Ueno S, Sakoda M, Iino S, Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et al: Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
65	Zhang J, Lu C, Zhang J, Kang J, Cao C and Li M: Involvement of ZEB1 and E-cadherin in the invasion of lung squamous cell carcinoma. Mol Biol Rep. 40:949–956. 2013. View Article : Google Scholar : PubMed/NCBI
66	Campos-Viguri GE, Jiménez-Wences H, Peralta-Zaragoza O, Torres-Altamirano G, Soto-Flores DG, Hernández-Sotelo D, Alarcón-Romero Ldel C, Jiménez-López MA, Illades-Aguiar B and Fernández-Tilapa G: miR-23b as a potential tumor suppressor and its regulation by DNA methylation in cervical cancer. Infect Agents Cancer. 10:422015. View Article : Google Scholar
67	Xue M, Pang H, Li X, Li H, Pan J and Chen W: Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 107:18–27. 2016. View Article : Google Scholar
68	Lei H, Gao Y and Xu X: LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin (Shanghai). 49:588–597. 2017. View Article : Google Scholar : PubMed/NCBI
69	Rice MA, Ishteiwy RA, Magani F, Udayakumar T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R, et al: The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related. Oncogene. 35:4752–4761. 2016. View Article : Google Scholar : PubMed/NCBI
70	Zeinali T, Mansoori B, Mohammadi A and Baradaran B: Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother. 109:195–207. 2019. View Article : Google Scholar : PubMed/NCBI
71	Chen Q, Zhou L, Ye X, Tao M and Wu J: miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3. Pathol Res Pract. 216:1528722020. View Article : Google Scholar
72	Lin H, Xu X, Chen K, Fu Z, Wang S, Chen Y, Zhang H, Niu Y, Chen H, Yu H, et al: LncRNA CASC15, MiR-23b cluster and SMAD3 form a novel positive feedback loop to promote Epithelial-Mesenchymal transition and metastasis in ovarian cancer. Int J Biol Sci. 18:1989–2002. 2022. View Article : Google Scholar
73	Gao M, Miao L, Liu M, Li C, Yu C, Yan H, Yin Y, Wang Y, Qi X and Ren J: miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 7:59714–59726. 2016. View Article : Google Scholar
74	Gao R, Fang C, Xu J, Tan H, Li P and Ma L: LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch Biochem Biophys. 663:183–191. 2019. View Article : Google Scholar : PubMed/NCBI
75	Wang Y, Tu MJ and Yu AM: Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs. Front Pharmacol. 15:14234162024. View Article : Google Scholar
76	Wang Y, Wang Y, Qin Z, Cai S, Yu L, Hu H and Zeng S: The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 17:291–306. 2021. View Article : Google Scholar
77	An Y, Zhang Z, Shang Y, Jiang X, Dong J, Yu P, Nie Y and Zhao Q: miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 6:e17662015. View Article : Google Scholar : PubMed/NCBI
78	Norouzi-Barough L, Sarookhani M, Salehi R, Sharifi M and Moghbelinejad S: CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran J Basic Med Sci. 21:181–187. 2018.
79	Lei ZN, Teng QX, Wu ZX, Ping FF, Song P, Wurpel JND and Chen ZS: Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. MedComm (2020). 2:765–777. 2021. View Article : Google Scholar : PubMed/NCBI